News

Fierce Biotech56m
Seyltx reserves option to boost chronic cough pipeline with 8 GluN2B antagonists
The widely used cough suppressant dextromethorphan is an NMDA receptor antagonist. Seyltx and Atlanta-based NeurOp are ...
Fierce Biotech2h
Chasing Sarepta, RegenXBio links DMD gene therapy to improved outcomes
RegenXBio has shared updated phase 1/2 data on its Duchenne muscular dystrophy (DMD) gene therapy, providing evidence that ...
Fierce Biotech3h
Corcept unveils promising survival data from failed phase 2 ALS trial
Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...
Fierce Biotech6h
Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager
Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...
Fierce Biotech18h
Rapt Therapeutics cuts staff for 2nd time in less than a year, continuing fallout from FDA hold
Rapt Therapeutics has conducted its second round of layoffs in just under a year, continuing a period of upheaval following ...
Fierce Biotech22h
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...